AstraZeneca PLC's Farxiga received the U.S. Food and Drug Administration's fast-track status to reduce the risk of two types of heart failure.
The medicine, which is also known as dapagliflozin, is being developed to reduce the risk of cardiovascular death in patients with either reduced ejection fraction, or HFrEF, or preserved ejection fraction, or HFpEF.
![]() |
Heart failure affects about 64 million people worldwide and at least half of them have a reduced ejection fraction.
The fast-track designation is based on two late-stage trials, dubbed DAPA-HF and DELIVER, conducted to test Farxiga in HFrEF patients and HFpEF patients respectively.
Previously, the Cambridge, U.K.-based company's medicine received fast-track status by the U.S. FDA to help delay the progression of renal failure.

